These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 20116234)

  • 1. Genetic and cellular mechanisms of oncogenesis.
    Hunter T; Marais R
    Curr Opin Genet Dev; 2010 Feb; 20(1):1-3. PubMed ID: 20116234
    [No Abstract]   [Full Text] [Related]  

  • 2. [Value of inhibition of signal transduction and epigenetic therapy concepts in cancer therapy].
    Tabernero J; Kaye S
    Onkologie; 2005 Oct; 28 Suppl 4():43-7. PubMed ID: 16285040
    [No Abstract]   [Full Text] [Related]  

  • 3. [Future prospects of RNA interference in cancer therapies].
    Ashihara E
    Rinsho Ketsueki; 2009 Oct; 50(10):1577-88. PubMed ID: 19915369
    [No Abstract]   [Full Text] [Related]  

  • 4. New targets in oncology drug development.
    Verweij J
    Clin Adv Hematol Oncol; 2005 Oct; 3(10):754-5. PubMed ID: 16258482
    [No Abstract]   [Full Text] [Related]  

  • 5. STATs in oncogenesis.
    Bowman T; Garcia R; Turkson J; Jove R
    Oncogene; 2000 May; 19(21):2474-88. PubMed ID: 10851046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor targeting based on the effect of enhanced permeability and retention (EPR) and the mechanism of receptor-mediated endocytosis (RME).
    Tanaka T; Shiramoto S; Miyashita M; Fujishima Y; Kaneo Y
    Int J Pharm; 2004 Jun; 277(1-2):39-61. PubMed ID: 15158968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Molecular targeting as a new strategy for cancer chemotherapy].
    Nakano S
    Fukuoka Igaku Zasshi; 2000 Jan; 91(1):1-7. PubMed ID: 10714011
    [No Abstract]   [Full Text] [Related]  

  • 8. Role of the cytoskeletal protein paxillin in oncogenesis.
    Sattler M; Pisick E; Morrison PT; Salgia R
    Crit Rev Oncog; 2000; 11(1):63-76. PubMed ID: 10795627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Introduction to resistance to anticancer agents.
    Kruh GD
    Oncogene; 2003 Oct; 22(47):7262-4. PubMed ID: 14576836
    [No Abstract]   [Full Text] [Related]  

  • 10. Inhibitors of cellular signaling targets: designs and limitations.
    Vlahos CJ; Stancato LF
    Methods Mol Biol; 2004; 273():87-102. PubMed ID: 15308795
    [No Abstract]   [Full Text] [Related]  

  • 11. Genomics and proteomics approaches in understanding tumor angiogenesis.
    Mittal V; Nolan DJ
    Expert Rev Mol Diagn; 2007 Mar; 7(2):133-47. PubMed ID: 17331062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The critical need for cancer biometrics: quantitative, reproducible measures of cancer to define response to therapy.
    Lotze MT
    Curr Opin Investig Drugs; 2003 Jun; 4(6):649-51. PubMed ID: 12901221
    [No Abstract]   [Full Text] [Related]  

  • 13. Cancer proteomics and its application to discovery of therapy response markers in human cancer.
    Smith L; Lind MJ; Welham KJ; Cawkwell L;
    Cancer; 2006 Jul; 107(2):232-41. PubMed ID: 16752413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platinum resistance. Experimental and clinical status.
    Los G; Muggia FM
    Hematol Oncol Clin North Am; 1994 Apr; 8(2):411-29. PubMed ID: 8040146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth and differentiation control.
    Francis GE; Dómine M
    Cancer Chemother Biol Response Modif; 1992; 13():230-85. PubMed ID: 1389911
    [No Abstract]   [Full Text] [Related]  

  • 16. Tight junctions.
    Anderson JM; Van Itallie CM
    Curr Biol; 2008 Oct; 18(20):R941-3. PubMed ID: 18957244
    [No Abstract]   [Full Text] [Related]  

  • 17. Impact of viral oncogenesis on responses to anti-cancer drugs and irradiation.
    Efferth T; Grassmann R
    Crit Rev Oncog; 2000; 11(2):165-87. PubMed ID: 11005511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted cancer therapy.
    Sawyers C
    Nature; 2004 Nov; 432(7015):294-7. PubMed ID: 15549090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epithelial proteomics in multiple organs and tissues: similarities and variations between cells, organs, and diseases.
    Zhao H; Adler KB; Bai C; Tang F; Wang X
    J Proteome Res; 2006 Apr; 5(4):743-55. PubMed ID: 16602680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
    Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
    J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.